Pharmaceutical

Health Canada approves Acadia’s DAYBUE for Rett syndrome

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.

Oct 18, 2024 - 04:00
Health Canada approves Acadia’s DAYBUE for Rett syndrome
Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome.
Read the original article

Tags:

Previous Article

Glaukos eyes FDA approval for ocular therapy after Phase III win

Next Article

Lexicon partners Viatris for global expansion of sotagliflozin

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Researchers try to tease out possible ties between long Covid and menopause

Researchers try to tease out possible ties between long...

Oct 20, 2023

STAT+: For hospitals after No Surprises Act, physician subsidies are ‘the new contract labor’

STAT+: For hospitals after No Surprises Act, physician ...

Oct 30, 2023

SNIPR celebrates US court’s favourable ruling on CRISPR patent

SNIPR celebrates US court’s favourable ruling on CRISPR...

Jul 17, 2023